These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 23674352

  • 1. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P.
    J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
    [Abstract] [Full Text] [Related]

  • 2. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P.
    Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
    [Abstract] [Full Text] [Related]

  • 3. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR, Almenara JA, Coe S, Grant S.
    Cancer Res; 2007 Oct 01; 67(19):9490-500. PubMed ID: 17909059
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
    Tang Y, Yacoub A, Hamed HA, Poklepovic A, Tye G, Grant S, Dent P.
    Cancer Biol Ther; 2012 May 01; 13(7):567-74. PubMed ID: 22406992
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
    Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P.
    Mol Pharmacol; 2013 Oct 01; 84(4):562-71. PubMed ID: 23877009
    [Abstract] [Full Text] [Related]

  • 9. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM.
    Clin Cancer Res; 2014 Mar 01; 20(5):1274-1287. PubMed ID: 24520095
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 01; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 13. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
    Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS.
    Cancer Biol Ther; 2011 Aug 01; 12(3):229-38. PubMed ID: 21725212
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S, Sinicrope FA.
    Mol Cancer Ther; 2010 Mar 01; 9(3):742-50. PubMed ID: 20197401
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
    Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, Houghton PJ, Voelkel-Johnson C, Grant S, Dent P.
    Mol Pharmacol; 2009 Aug 01; 76(2):342-55. PubMed ID: 19483104
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y.
    Oncol Res; 2017 Nov 02; 25(9):1543-1553. PubMed ID: 28276313
    [Abstract] [Full Text] [Related]

  • 17. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
    Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, Dent P.
    Mol Cancer Ther; 2008 Sep 02; 7(9):2633-48. PubMed ID: 18790746
    [Abstract] [Full Text] [Related]

  • 18. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
    Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH.
    J Biol Chem; 2007 Oct 12; 282(41):29831-46. PubMed ID: 17698840
    [Abstract] [Full Text] [Related]

  • 19. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
    Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR, Schuchmann M, Schulze-Bergkamen H.
    World J Gastroenterol; 2009 Dec 21; 15(47):5924-35. PubMed ID: 20014456
    [Abstract] [Full Text] [Related]

  • 20. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J, Chen Y, Wan J, Liu X, Yu C, Li W.
    Br J Pharmacol; 2014 Jul 21; 171(13):3182-95. PubMed ID: 24571452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.